Only a small percent of patients eligible for assistance programs actually enroll, and Vivor is working with pharmaceutical companies to make the process of using patient assistance programs smoother, said Ian Manners, founder and CEO of Vivor.
Only a small percent of patients eligible for assistance programs actually enroll, and Vivor is working with pharmaceutical companies to make the process of using patient assistance programs smoother, said Ian Manners, founder and CEO of Vivor.
Transcript
What has participation by industry been in Vivor’s work? What do they feel they get out of it?
For industry, there’s always been a challenge of: I want to make sure I’m addressing out-of-pocket costs everywhere, but programs that have been available for years often go very underutilized. We often sometimes see for cancer patients, even though the eligibility rules are generous, over 90% of patients are eligible for assistance programs, in some cases fewer than 20% of patients are actually getting enrolled. The gap is huge, and we know that industry partners are very interested in increasing the utilization of programs so that they can help patients get on appropriate therapy.
We take in a very provider-first view—we make our software first for providers. They are our customer. We make our results completely comprehensive. There’s no pay-for-play at all. But, the way that we do work with industry partners is to make the enrollment process and the process of using an assistance program much smoother. We can work with pharma companies to make it a one-click enrollment using the information that’s already in our platform to get a patient set up and enrolled in an assistance program and then send back the results in real time. So, industry partners are very excited about that ability to improve the experience, and as a result get many more patients who need, deserve, financial assistance enrolled in their programs.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More